Abstract:4148 Apoptosis, or programmed cell death, plays a key role in normal tissue homeostasis ensuring a proper balance between cell production and cell loss. Anti-apoptotic Bcl-2-family proteins are key regulators of the apoptotic pathway and their increased expression in human malignancies is associated with disease progression, tumor resistance to chemotherapy, radiation and poor clinical outcome. Recently,a novel Bcl-2/Bcl-xL/Bcl-w inhibitor (ABT-737) has been developed, which is highly potent in killing tumor cells displayinghigh levels of Bcl-2 and dependent upon Bcl-2 forsurvival. However, ABT-737 exhibits a relatively low affinityfor Mcl-1 and is considerably less efficient in killing tumor cellsexpressing high Mcl-1 levels. Several groups provide strong evidence that Mcl-1 is the major factor that causes resistance to ABT-737 in cancer cells derived from diverse solid tumors, and one approach for overcoming this resistance could be the combination of ABT-737 with agentscapable of down-regulating/inhibiting Mcl-1. Here, we describe a high throughput screening approach that led to the identification of several chemical classes, small molecule Mcl-1 inhibitors. The compounds were characterized in a number of assays including in vitro binding using fluorescence polarization based assay, SPR solution competitive assay, heteronuclear single quantum correlation (HSQC) NMR spectroscopy, pull-down assay, functional assay for cytochrome c and Smac release and a cell-based viability assay with human cancer cells. The most potent of the inhibitors identified was compound 65, which binds to Mcl-1 protein with IC50 of 0.3 μM, showing >100-fold selectivity over Bcl-xL and 60-fold selectivity over Bcl-2 protein. 15N HSQC spectra conclusively showed that compound 65 interacts with the BH3 domain in Mcl-1 protein and many residues in the BH3 binding groove of Mcl-1 protein were affected by 65. Furthermore, pull-down assay demonstrates that the compound 65 is able in dose dependent manner to disrupt interactions between endogenous Mcl-1 protein and biotin labeled Noxa and Bid BH3 peptides, but not between Bid BH3 peptide and other members of Bcl-2 family (Bcl-xL and Bcl-2). Functional studies showed that compound 65 effectively antagonizes recombinant Mcl-1 protein and promotes release of cytochrome c and Smac from isolated mitochondria. Compound 65 displayed cytotoxicity with IC50 from 3 μM to 8 μM against a number of human cancer cell lines with high level of Mcl-1 protein. Collectively, these data indicate that 65 represents a novel and bone fide small-molecule inhibitor of Mcl-1 and a promising lead compound for further optimization toward developing a new class of anticancer drugs by targeting the Mcl-1 protein.

Clitocine targets Mcl-1 to induce drug-resistant human cancer cell apoptosis in vitro and tumor growth inhibition in vivo

Clitocine Potentiates TRAIL-mediated Apoptosis in Human Colon Cancer Cells by Promoting Mcl-1 Degradation

Clitocine Induces Apoptosis and Enhances the Lethality of ABT-737 in Human Colon Cancer Cells by Disrupting the Interaction of Mcl-1 and Bak.

Small interfering RNA targeting mcl-1 enhances proteasome inhibitor-induced apoptosis in various solid malignant tumors

Clitocine enhances the drug sensitivity of colon cancer cells by promoting FBXW7-mediated MCL-1 degradation via inhibiting the A2B/cAMP/ERK axis

Clitocine Reversal of P-Glycoprotein Associated Multi-Drug Resistance Through Down-Regulation of Transcription Factor NF-κB in R-HepG2 Cell Line

Anti-proliferative Effect of Clitocine from the Mushroom Leucopaxillus Giganteus on Human Cervical Cancer HeLa Cells by Inducing Apoptosis

Discovery and Characterization of New Small-Molecule Inhibitors of Mcl-1 by High-Throughput Screening

Targeting Mcl-1 for the Therapy of Cancer

Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)

Targeting Mcl-1 Sensitizes Human Esophageal Squamous Cell Carcinoma Cells to Cisplatin-Induced Apoptosis

Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a TP53- and BAX- Dependent Manner

Upregulation of Mcl-1 inhibits JQ1-triggered anticancer activity in hepatocellular carcinoma cells.

Small molecule Mcl-1 inhibitor for triple negative breast cancer therapy

Discovery of Mcl-1 inhibitors through virtual screening, molecular dynamics simulations and in vitro experiments

Mcl-1 targeting strategies unlock the proapoptotic potential of TRAIL in melanoma cells

CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax

Discovery of a Copper-Based Mcl-1 Inhibitor as an Effective Antitumor Agent

MCL-1 siRNA Reverses the Chemoresistance of Cisplatin-resistant SW480 Cells via the Pathway of Mitochondrial Apoptosis

Targeting Mcl-1 for Radiosensitization of Pancreatic Cancers

Discovery of Marinopyrrole A (maritoclax) As a Selective Mcl-1 Antagonist That Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation*